Effect of cancer patient navigation services on Health-Illness transition readiness among women with newly diagnosed breast cancer: a Quasi-Experimental study
NCT ID NCT07892157
First seen Oct 23, 2026 · Last updated Oct 23, 2026
Summary
This study evaluated whether Cancer Patient Navigation (CPN) services could improve readiness for the transition from breast cancer diagnosis to treatment. The study involved 64 women newly diagnosed with stage I-IIIA breast cancer who experienced high psychological distress at a cancer referral hospital in Indonesia. Participants were assigned to either a navigation group or a standard care group without randomization. Women in the navigation group received a 30-day support program that included education about breast cancer, guidance on treatment preparation, assistance with care coordination, and emotional support. The program included three to four hospital-based sessions during scheduled visits, a patient education booklet, and online nutrition education. Women in the comparison group received standard care. Participants' readiness to manage changes related to their cancer diagnosis and prepare for treatment was assessed before and after the study using the Measurement of Transitions in Cancer Scale. The study aimed to determine whether women receiving navigation services experienced greater improvements in transition readiness than those receiving standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
64 people
The number who actually took part.
- Started
-
Jan 2026
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: The inclusion criteria were: (1) newly diagnosed breast cancer confirmed by histopathological and/or radiological examination; (2) stage I-IIIA breast cancer; (3) no prior cancer-directed treatment, including surgery, chemotherapy, or radiotherapy, at baseline; (4) high psychological distress, defined as a score ≥7 on the National Comprehensive Cancer Network Distress Thermometer (NCCN-DT); and (5) willingness of patients and/or family members to use online meeting platforms or digital communication applications during the study. Exclusion Criteria: 1. Patients with a history of cancer other than breast cancer. 2. Patients who are unwilling to participate as respondents.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RSUP Dr. Sardjito
Yogyakarta, 55281, Indonesia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phase II, Open-Label, randomized study comparing antiangiogenic therapy combined with immunotherapy and capecitabine versus Investigator's choice in patients with circulating tumor DNA-Positive stage II-III Triple-Negative breast cancer who with residual disease after neoadjuvant therapy
- Brazilian randomized study - impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery
- Toxicity and outcome of whole breast hypofractionated radiotherapy without boost: results of a homogeneous single institution experience
- Evaluation of the effect of amantadine in the prevention of Paclitaxel-Induced peripheral neuropathy in breast cancer patients
- Five fractions ultrahypofractionated whole breast radiotherapy and simultaneous integrated boost to the tumor bed, for breast cancer patients with unfavorable characteristics
- A post-market multi-center prospective study to assess the ability of the portable scalp cooling system (PSCS) to prevent hair loss in women receiving specific chemotherapy regimens for breast cancer stages I-III.